Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Granulomatous Disease Clear all
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Not listed No phase listed Observational

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

NCT02082353
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

NCT00001765
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Nexell Isolex with T-cell Depletion, Baxter isolex 300i
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of IFN-γ on Innate Immune Cells

NCT02609932
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Administration of drug (Interferon-gamma 1-b) subcutaneously
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

NCT00001280
View directory record Official record
Conditions
Mycoses
Interventions
itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 8:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

NCT02282904
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Sirolimus, Donor peripheral blood stem cells., Cyclophosphamide post transplant, Total body 200cGy, Cyclophosphamide, Fludarabine, Busulfan
Drug · Biological · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

NCT06876363
View directory record Official record
Conditions
X-Linked Chronic Granulomatous Disease
Interventions
EN-374
Genetic
Lead sponsor
Ensoma
Industry
Eligibility
3 Months and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational

Granulomatous Mastitis Current Approach and Treatment

NCT02667132
View directory record Official record
Conditions
Granulomatous, Mastitis
Interventions
Not listed
Lead sponsor
Granulomatous Mastitis Working Group
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT05104723
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions
XELJANZ (tofacitinib)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

NCT02629120
View directory record Official record
Conditions
Chronic Granulomatous Disease Transplant
Interventions
Alemtuzumab, Busulfan, Sirolimus, Cyclophosphamide, Total Body Irradiation, Peripheral blood stem cells
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

NCT00001405
View directory record Official record
Conditions
Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked, Genetic Disease, Inborn
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational

Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease

NCT02233036
View directory record Official record
Conditions
CGD
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 26 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Early Phase 1 Interventional

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

NCT05600907
View directory record Official record
Conditions
Chronic Granulomatous Disease, CGD
Interventions
JSP191
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Terminated No phase listed Observational

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

NCT05915897
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Specimen Donation
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational

Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders

NCT00005933
View directory record Official record
Conditions
Chediak Higashi Syndrome, Chronic Granulomatous Disease, Job's Syndrome, Leukocyte Disorder
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 8:04 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

NCT00919503
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

NCT05333471
View directory record Official record
Conditions
Chronic Granulomatous Disease-associated Colitis
Interventions
MTP 101-LF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 25, 2026, 8:04 AM EDT